ASCO GI 2023 | ctDNA monitoring to assess clinical outcomes in mCRC treated with front-line chemotherapy

Michele Ghidini, MD, PhD, Policlinico di Milano, Milan, Italy, discusses circulating tumor DNA (ctDNA) dynamics and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing front-line chemotherapy. In this investigation, ctDNA monitoring was found to represent an early indicator of benefit from systemic therapy in patients with mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ